secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001159036-26-000053
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme names Darren Snellgrove as CFO, effective June 8, 2026
---------------------------------------------------------------

- Darren Snellgrove appointed CFO effective June 8, 2026; previously VP IR at Johnson & Johnson and CFO of its Pharmaceuticals sector.
- Compensation: $670,000 annual salary, 50% bonus target, $350,000 sign-on cash bonus, and $7.2M new-hire equity awards ($3.2M RSUs + $4M options).
- 2027 long-term incentive minimum $4M; make-whole RSUs vest over 3 years, stock options vest 25% after 1 year then monthly.
- David Ramsay, interim CFO, will assume advisory role effective June 8, 2026 to assist transition.
- Snellgrove holds MBA from Villanova, BA from University of Southampton; no family relationships or material interests in transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000053/0001159036-26-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000053/halo-20260430.htm
  HTML page:      https://secwatch.observer/filing/0001159036-26-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer